Literature DB >> 19197596

Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics.

Adam R Winstock1, Toby Lea, Anthony P Jackson.   

Abstract

This study aimed to develop a better understanding of the motives for suspected buprenorphine diversion during supervised dosing. Structured interviews were conducted with clients after 71 episodes of diversion at 3 opioid substitution treatment clinics in Sydney, Australia. Interviews were conducted by the clinic manager. An equivalent number of suspected episodes involved diversion via removal of buprenorphine from the mouth (n = 35), and secretion of buprenorphine in the mouth (n = 32). Denial of diversion occurred in 45% of suspected episodes and was significantly associated with secretion of buprenorphine in the mouth (P < .0001), suggesting a possible misunderstanding between clinicians and clients to what constitutes diversion. Motivations for diversion included "stockpiling" for later sublingual use (n = 15), discarding buprenorphine (n = 11), and giving it to another person (n = 5). A consistent definition of diversion of supervised dosed of buprenorphine is required. Diversion of supervised doses may represent a single episode of nonadherence to dosing instructions or more significant ambivalence over treatment. Responses to suspected diversion should aim to minimise harm and maximise treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19197596     DOI: 10.1080/10550880802545036

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  5 in total

1.  A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.

Authors:  Yatan Pal Singh Balhara; Raka Jain
Journal:  Innov Clin Neurosci       Date:  2012-07

2.  Opioid substitution therapy for dependent health care practitioners: approach with caution.

Authors:  Paul H Earley
Journal:  Mayo Clin Proc       Date:  2012-08       Impact factor: 7.616

3.  Buprenorphine maintenance therapy in opioid-addicted health care professionals returning to clinical practice: a hidden controversy.

Authors:  Heather Hamza; Ethan O Bryson
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

Review 4.  Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Josiah D Rich
Journal:  Curr Drug Abuse Rev       Date:  2011-03

5.  Provision of opioid substitution therapy services in Australian pharmacies.

Authors:  B B Chaar; J R Hanrahan; C Day
Journal:  Australas Med J       Date:  2011-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.